Deutsche Märkte schließen in 3 Stunden 2 Minuten

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
271,91+2,98 (+1,11%)
Börsenschluss: 04:00PM EDT
271,91 0,00 (0,00%)
Vorbörslich: 08:16AM EDT

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter26.700

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Robert A. BradwayChairman, CEO & President6,73MN/A1963
Mr. Peter H. GriffithExecutive VP & CFO3,07MN/A1959
Mr. Esteban SantosExecutive Vice President of Operations3,01MN/A1968
Dr. David M. Reese M.D.Executive VP & Chief Technology Officer3,4MN/A1963
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations3,24MN/A1967
Mr. Matthew C. BuschChief Accounting Officer & VP of FinanceN/AN/A1974
Mr. Mike ZahigianSenior VP & Chief Information OfficerN/AN/AN/A
Dr. James E. Bradner M.D.Executive VP of Research and Development & Chief Scientific OfficerN/AN/A1972
Justin G. ClaeysVice President of Investor RelationsN/AN/AN/A
Mr. Jonathan P. GrahamExecutive VP, General Counsel & Secretary2,44MN/A1961
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Corporate Governance

Amgen Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 2. Die grundlegenden Scores sind Audit: 2, Vorstand: 8, Shareholderrechte: 1, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.